RxDoctor Payments Data

Craig Comiter, MD

Urology · Stanford, CANPI 1780657171

Payments from drug & device makers

$63,942in general payments, 2019–2025

Across 106 payments — averaging $603.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Procept Biorobotics Corporation$27K
  • Coloplast$12K
  • Axonics, Inc.$8K
  • Saluda Medical Americas, Inc.$5K
  • Boston Scientific$5K
  • Shionogi Inc$2K
  • plus $5K from 13 others
$20,543in research payments, 2019–2025

Across 5 payments — averaging $4108.68 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Coloplast$21K

What the payments were for

  • Consulting fees$39,55869%
  • Speaking & faculty fees$2,9505%
  • Travel & lodging$11,76220%
  • Food & beverage$3,1335%
  • Education$960%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$63,942 in reported general payments places this provider in the 90th percentile of 1,324 urology providers in California.

See all urology providers in California

Medicare billing

Part B allowed, 2024
$224,614
Medicare patients
774
Services billed
1,671

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
MyrbetriqMirabegron344$249,608
GemtesaVibegron129$151,371
Mirabegron ErMirabegron15$9,828
Methenamine Hippurate57$7,081
Tamsulosin Hcl217$4,793
Finasteride257$3,719
Trospium Chloride80$2,699
Estradiol26$1,806
Dutasteride15$1,447
Trimethoprim36$1,416
Desmopressin Acetate13$894
Alfuzosin Hcl ErAlfuzosin Hcl31$808
Cephalexin51$608
Amoxicillin-Clavulanate PotassAmoxicillin/Potassium Clav40$306
Amitriptyline Hcl11$148

Paid to pharmacies, not to this prescriber.

Other urology in Stanford

See the full list for California

Where these figures come from

Is this you, or does something look wrong? →